Work

Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.11532

Authors: William D. Tap, Gregory Michael Cote, Howard A. Burris, Lia Gore, Muralidhar Beeram, Anthony Paul Conley, Diego A. Gianolio, Zhe Qu, Camelia Gliser, Shuchi Sumant Pandya, Jonathan C. Trent

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Massachusetts General Hospital, Sarah Cannon, Children's Hospital Colorado, University of Colorado Anschutz, University of Colorado Denver, South Texas Accelerated Research Therapeutics, The University of Texas MD Anderson Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center

Language: English

Topic: Bone Tumor Diagnosis and Treatments

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379280672

Cites:

Cited by: 4

Related to: 10